Chi Sheng Pharma & Biotech Co (4111) Fair Value & Analysis
Healthcare · TW · Market cap 1.8B TWD
Fair value as of: Jul 23, 2026
From 26 valuation models · updated 18 days ago
Share price −1.6% over the past month.
A solid business, screening 99% undervalued on our models.
What matters now
- The rarer combination: high quality (70/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (42.97 TWD). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.
How to read this chart
60‑month range 20.72 TWD – 36.05 TWD · fair‑value band 42.97 TWD – 73.56 TWD · the 29.85 TWD price screens below the 59.40 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 23, 2026.
Analysis
Chi Sheng Pharma & Biotech Co (4111) currently trades at 29.85 TWD, while our model-based Fair Value estimate is 59.40 TWD, implying the stock looks roughly 99.0% undervalued today. The Quality Score stands at 70/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Chi Sheng Pharma & Biotech Co generated revenue of 1.4B TWD at a net margin of 12.7%. Revenue grew 11.6% year over year. It earns a return on equity of 13.1%. The balance sheet holds a net cash position of 166M TWD. Fundamentals as of Jul 23, 2026
Our scenario range runs from 42.97 TWD (bear case) to 73.56 TWD (bull case); at 29.85 TWD, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 99%, 4111 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (54.92 TWD) versus Dividend Discount (11.97 TWD). Highest evidence: Residual Income (76).
Notify me when 4111 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 53
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally.
Full company description
Chi Sheng Pharma & Biotech Co., Ltd manufactures, processes, imports, exports, and sells western medicines, cosmetics, health food products, medical devices, and animal medicines in Taiwan and internationally. Its product portfolio includes antibiotics and chemotherapeutic agents; plasma substitutes and amino acid preparations; water nutrients and electrolyte preparations; vitamins; hepatotropic agents; hormones and adrenal cortical steroids; autonomic nerve agents; antihistamines and antipruritics; antipyretics and analgesics; antitussives and anti-asthmatics; gastro-intestinal preparations; local anesthetic preparations; hemodialysis concentrate and external solutions; peritoneal dialysis solutions; and others. The company also offers medical devices, fat emulsion products, anesthetic products, hemostatic solutions, food and health food products, functional drinks, skin care products and cosmetics, and veterinary medicinal products. In addition, it provides externally applied medicines, including contact lens, and salt and iodine solutions. Chi Sheng Pharma & Biotech Co., Ltd was founded in 1962 and is headquartered in Hukou, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chi Sheng Pharma & Biotech Co reported revenue of 1.4B TWD in FY2025 versus 1.0B TWD in FY2021, a compound +7.7%/yr. Reported net income was 164M TWD in FY2025, compounding +19.4%/yr from FY2021.
Watch 4111: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Chi Sheng Pharma & Biotech Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chi Sheng Pharma & Biotech Co (4111) overvalued or undervalued?
What is the fair value of 4111?
What is the quality score of 4111?
What is the revenue of Chi Sheng Pharma & Biotech Co (4111)?
What is the net profit margin of 4111?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Chi Sheng Pharma & Biotech Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.